Exhibit 6
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, the undersigned hereby (i) agree to the joint filing with all other Reporting Persons (as such term is defined in the statement on Schedule 13D described below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $.001 per share, of Cesca Therapeutics Inc. and (ii) agree that this Agreement be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.
Dated: April 27, 2018
| Boyalife Investment Inc. |
| |
|
|
|
|
| By: | /s/ Xiaochun Xu |
|
|
| (Signature) |
|
|
|
|
|
Name: | Dr. Xiaochun Xu | ||
Title: | President | ||
Boyalife Group Inc. | |||
By: | /s/ Xiaochun Xu | ||
(Signature) | |||
Name: | Dr. Xiaochun Xu | ||
Title: | President | ||
Boyalife Asset Holding II, Inc. | |||
By: | /s/ Xiaochun Xu | ||
(Signature) | |||
Name: | Dr. Xiaochun Xu | ||
Title: | President | ||
Boyalife (Hong Kong) Limited | |||
By: | /s/ Yishu Li | ||
(Signature) | |||
Name: | Yishu Li | ||
Title: | President | ||
/s/ Xiaochun Xu | |||
Dr. Xiaochun Xu, individually | |||
/s/ Yishu Li | |||
Yishu Li, individually | |||
